{"@context":"https:\/\/schema.org\/","@type":"CollectionPage","@id":"https:\/\/www.regionalcancercare.org\/news\/category\/lymphoma\/#CollectionPage","headline":"Lymphoma Category","description":"","url":"https:\/\/www.regionalcancercare.org\/news\/category\/lymphoma\/","hasPart":[{"@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/the-difference-between-hodgkin-and-non-hodgkin-lymphoma\/","headline":"The Difference between Hodgkin and Non-Hodgkin Lymphoma","url":"https:\/\/www.regionalcancercare.org\/news\/the-difference-between-hodgkin-and-non-hodgkin-lymphoma\/","datePublished":"2023-09-26","dateModified":"2023-11-01","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/the-difference-between-hodgkin-and-non-hodgkin-lymphoma\/","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/Microscope-image-of-non-Hodgkin-lymphoma-cells.jpg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/Microscope-image-of-non-Hodgkin-lymphoma-cells.jpg","height":506,"width":900},"keywords":["Blood and Marrow Transplant"]},{"@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/weed-killer-and-non-hodgkins-lymphoma\/","headline":"Weed Killer and Non-Hodgkin Lymphoma","url":"https:\/\/www.regionalcancercare.org\/news\/weed-killer-and-non-hodgkins-lymphoma\/","datePublished":"2023-07-13","dateModified":"2024-04-15","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/weed-killer-and-non-hodgkins-lymphoma\/","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/RCCA-weed-killer.jpg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/RCCA-weed-killer.jpg","height":600,"width":900},"keywords":null},{"@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/","headline":"Cancers Most Likely To Benefit From Targeted Monoclonal Immunotherapy","url":"https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/","datePublished":"2020-04-21","dateModified":"2025-12-03","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/cancers-most-likely-to-necessitate-targeted-monoclonal-immunotherapy\/","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/09\/Doctor-And-Patient-Talking.jpg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/09\/Doctor-And-Patient-Talking.jpg","height":600,"width":900},"keywords":["Treatments","Immunotherapy","targeted therapy"]},{"@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/hematologic-cancer-treatment-options\/","headline":"Treatments for Hematologic Cancers (Blood Cancers)","url":"https:\/\/www.regionalcancercare.org\/news\/hematologic-cancer-treatment-options\/","datePublished":"2020-04-07","dateModified":"2025-12-03","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/hematologic-cancer-treatment-options\/","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/09\/Doctors-Examining-Blood-Cells.jpg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/09\/Doctors-Examining-Blood-Cells.jpg","height":587,"width":900},"keywords":["clinical trials","Treatments","Radiation Therapy","Chemotherapy","Blood and Marrow Transplant"]},{"@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/how-immunotherapy-works\/","headline":"What Is Immunotherapy \u2013 and Is It Right for You?","url":"https:\/\/www.regionalcancercare.org\/news\/how-immunotherapy-works\/","datePublished":"2019-09-15","dateModified":"2021-11-11","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/how-immunotherapy-works\/","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/09\/Man-Receiving-Immunotherapy-Treatment.jpg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/09\/Man-Receiving-Immunotherapy-Treatment.jpg","height":600,"width":900},"keywords":["Treatments","Immunotherapy"]},{"@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/regional-cancer-care-associates-rcca-researchers-from-john-theurer-cancer-center-present-leading-edge-clinical-data-in-blood-cancers-at-american-society-of-hematology-meeting\/","headline":"Regional Cancer Care Associates (RCCA) Researchers from John Theurer Cancer Center Present Leading-Edge Clinical Data in Blood Cancers at American Society of Hematology Meeting","url":"https:\/\/www.regionalcancercare.org\/news\/regional-cancer-care-associates-rcca-researchers-from-john-theurer-cancer-center-present-leading-edge-clinical-data-in-blood-cancers-at-american-society-of-hematology-meeting\/","datePublished":"2015-12-09","dateModified":"2021-12-14","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/regional-cancer-care-associates-rcca-researchers-from-john-theurer-cancer-center-present-leading-edge-clinical-data-in-blood-cancers-at-american-society-of-hematology-meeting\/","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/COA.png","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/COA.png","height":"193","width":"200"},"keywords":["Press Release"]},{"@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/jtcc-announces-positive-results-with-new-targeted-biological-in-indolent-non-hodgkin-lymphoma\/","headline":"JTCC Announces Positive Results with New Targeted Biological in Indolent Non-Hodgkin Lymphoma","url":"https:\/\/www.regionalcancercare.org\/news\/jtcc-announces-positive-results-with-new-targeted-biological-in-indolent-non-hodgkin-lymphoma\/","datePublished":"2014-01-23","dateModified":"2021-11-11","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/jtcc-announces-positive-results-with-new-targeted-biological-in-indolent-non-hodgkin-lymphoma\/","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/COA.png","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/COA.png","height":"193","width":"200"},"keywords":["Press Release","Treatments","Immunotherapy"]},{"@type":"BlogPosting","@id":"https:\/\/www.regionalcancercare.org\/news\/jtcc-presents-genomic-data-on-poor-risk-diffuse-large-b-cell-lymphoma-using-targeted-dna-and-rna\/","headline":"JTCC Presents Genomic Data on Poor Risk Diffuse Large B-Cell Lymphoma Using Targeted DNA and RNA…","url":"https:\/\/www.regionalcancercare.org\/news\/jtcc-presents-genomic-data-on-poor-risk-diffuse-large-b-cell-lymphoma-using-targeted-dna-and-rna\/","datePublished":"2013-12-10","dateModified":"2021-11-11","mainEntityOfPage":"https:\/\/www.regionalcancercare.org\/news\/jtcc-presents-genomic-data-on-poor-risk-diffuse-large-b-cell-lymphoma-using-targeted-dna-and-rna\/","author":{"@type":"Person","@id":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/#Person","name":"ceastway","url":"https:\/\/www.regionalcancercare.org\/news\/author\/ceastway\/","identifier":5,"image":{"@type":"ImageObject","@id":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/007b7979610c70c3cd4b24ed960fb78ff62c0b68401d393e79cb483d56812050?s=96&d=mm&r=g","height":96,"width":96}},"publisher":{"@type":"Organization","name":"Regional Cancer Care Associates","logo":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/logo.svg","width":506,"height":228}},"image":{"@type":"ImageObject","@id":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/COA.png","url":"https:\/\/www.regionalcancercare.org\/wp-content\/uploads\/2021\/08\/COA.png","height":"193","width":"200"},"keywords":["Press Release"]}],"about":["Lymphoma"]}